Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol And Pfizer Team Up To Develop Anticoagulant Apixaban In $1 Billion Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

In a separate agreement, the firms will also collaborate on the development of Pfizer’s preclinical metabolic disorder compounds.
Advertisement

Related Content

Bristol/Pfizer's Apixaban: Third To Market But Best-In-Class?
Pfizer Finds Backup For Aricept In Medivation’s Dimebon
With European Approval Imminent, J&J/Bayer File Rivaroxaban In The U.S.
Pfizer: Sun Setting On Blockbuster Model
Astellas, Daiichi Move Ahead With Factor Xa Programs
Pfizer Pipeline Update Includes Resubmission Plans For Osteoporosis Drug Lasofoxifene
Lipitor Sales Plummet 13 Percent In Q2 On Inventory Fluctuations, Generic Pressure
J&J/Bayer’s Once-Daily Rivaroxaban Superior To Lovenox In Phase III Trial
Two Pfizer Veterans To Leave Firm
Bristol-Myers Squibb Licenses Cardiovascular Antisense Target From Isis

Topics

Advertisement
UsernamePublicRestriction

Register

PS065957

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel